Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Demographic Features of Included Patients

From: Diagnostic and prognostic value of ventilatory power in pulmonary hypertension

Variables

Normal control (n = 177)

PH

 

Total (n = 502)

Non-CW (n = 310)

CW (n = 192)

P value#

Age, years

49 (37, 58)

39 (29, 54)**

41 (29, 54)

37 (29, 55)

0.541

Body mass index, kg/m2

23.2 (21.0, 25.1)

22.9 (20.4, 25.4)

23.0 (20.7, 25.6)

22.6 (20.2, 24.8)

0.101

Female, n (%)

125 (70.6)

332 (66.1)

210 (67.7)

122 (63.5)

0.334

Etiology of PH

    

0.542

  IPAH, n (%)

300 (59.8)

182 (58.7)

118 (61.5)

 

  CTEPH, n (%)

202 (40.2)

128 (41.3)

74 (38.5)

 

WHO FC

    

< 0.001

  I and II, n (%)

141 (79.7)

261 (52.0)

184 (59.4)

77 (40.1)

 

  III and IV, n (%)

36 (20.3)

241 (48.0)

126 (40.6)

115 (59.9)

 

NT-proBNP, ng/L

117.2 (46.9, 325.0)

993.7 (287.0, 2095.5)**

752.2 (202.7, 1952.3)

1328.5 (568.0, 2374.0)

< 0.001

6MWD, m

462.1 ± 88.2

403.5 (330.0, 464.8)**

414.0 (335.3, 473.3)

394.0 (315.5, 446.5)

0.044

Newly diagnosed, n (%)

291 (58.0)

178 (57.4)

113 (58.9)

0.752

Pulmonary diseases, n (%)

17 (9.6)

43 (8.6)

22 (7.1)

21 (10.9)

0.135

  Respiratory tract infection

5 (2.8)

16 (3.2)

9 (2.9)

7 (3.6)

 

  Bronchial asthma

3 (1.7)

3 (0.6)

1 (0.3)

2 (1)

 

  Emphysema

4 (2.3)

8 (1.6)

3 (1)

5 (2.6)

 

  Bronchiectasis

2 (1.1)

10 (2)

5 (1.6)

5 (2.6)

 

  Bronchitis

3 (1.7)

6 (1.2)

4 (1.3)

2 (1)

 

PH specific therapy

    

0.962

  None, n (%)

59 (11.8)

38 (12.3)

21 (10.9)

 

  Monotherapy, n (%)

315 (62.8)

192 (61.9)

123 (64.1)

 

  Double, n (%)

120 (23.9)

75 (24.2)

45 (23.4)

 

  Triple, n (%)

8 (1.6)

5 (1.6)

3 (1.6)

 

Intervention$, n (%)

120 (23.9)

79 (25.5)

41 (21.4)

0.292

  1. Data are presented as median (range) or number (percentage). CTEPH, chronic thromboembolic pulmonary hypertension; CW, clinical worsening; IPAH, idiopathic pulmonary arterial hypertension; NT-proBNP, N-terminal pro-brain natriuretic peptide; PH, pulmonary hypertension; 6MWD, 6-min walk distance; WHO FC, World Health Organization function class; $ Intervention including pulmonary endarterectomy and balloon pulmonary angioplasty. *P < 0.05, Normal control compared with patients with PH. **P < 0.001, Normal control compared with patients with PH. #Patients with clinical worsening compared with those without. Significant P values (< 0.05) are bolded